Paraganglioma & Pheochromocytoma Syndromes: Genetic Risk Assessment
|
|
- Camron James
- 5 years ago
- Views:
Transcription
1 Paraganglioma & Pheochromocytoma Syndromes: Genetic Risk Assessment 60 th Annual Spring Symposium for Houston Society of Clinical Pathologists Houston, TX April 6 th, 2019 Samuel Hyde, MMSc, CGC Certified Genetic Counselor Clinical Cancer Genetics University of Texas MD Anderson Cancer Center
2 Why Does This Matter? Horm Metab Res, 2012
3 Historically The 10% Rule for Pheochromocytoma & Paraganglioma 10% familial 10% extra-adrenal 10% malignant ~30-40% of all PCC/PGL are hereditary Eisenhofer et al Clin Biochem Rev 2017
4 (Very Brief) A & P Refresher Parasympathetic chain PGL Occur above the aortic arch, H&N typically non-functional glomus tumors (historically) Glomus jugular, vagal, jugulotympanicum, carotid body Sympathetic chain PGL Occur below the aortic arch Often functional (fight-orflight response regulation; catecholamine, metanephrines, dopamine) Extra-adrenal PGL, retroperitoneal PGL
5 (Very Brief) A & P Refresher Parasympathetic chain PGL Occur above the aortic arch, H&N typically non-functional glomus tumors (historically) Glomus jugular, vagal, jugulotympanicum, carotid body Sympathetic chain PGL Occur below the aortic arch Often functional (fight-orflight response regulation; catecholamine, metanephrines, dopamine) Extra-adrenal PGL, retroperitoneal PGL
6 Genetic Testing for Patients with PCC/PGL Pheochromocytomas/Paragangliomas represent a group of tumors with a HIGH hereditary burden (highest among hereditary benign and malignant neoplasms) Approximately 30-40% of all tumors associated with a germline mutation in a PCC/PGL predisposition gene This estimate increases with: Younger age (<40) Bilateral/multifocal tumors Malignant disease Family history of PCC/PGL Personal/family history consistent with syndromic presentation This estimate (may) decrease with: Older age (>50) Single, unilateral tumors particularly of H&N origin Intact SDHB immunohistochemistry
7 Genetic Testing for Patients with PCC/PGL Pheochromocytomas/Paragangliomas represent a group of tumors with a HIGH hereditary burden (highest among hereditary benign and malignant neoplasms) Approximately 30-40% of all tumors associated with a germline mutation in a PCC/PGL predisposition gene This estimate increases with: Younger age (<40) Bilateral/multifocal tumors Malignant disease Family history of PCC/PGL Personal/family history consistent with syndromic presentation This estimate (may) decrease with: Older age (>50) Single, unilateral tumors particularly of H&N origin Intact SDHB immunohistochemistry
8 Genetic Testing for Patients with PCC/PGL Pheochromocytomas/Paragangliomas represent a group of tumors with a HIGH hereditary burden (highest among hereditary benign and malignant neoplasms) Approximately 30-40% of all tumors associated with a germline mutation in a PCC/PGL predisposition gene This estimate increases with: Younger age (<40) Bilateral/multifocal tumors Malignant disease Family history of PCC/PGL Personal/family history consistent with syndromic presentation This estimate (may) decrease with: Older age (>50) Single, unilateral tumors particularly of H&N origin Intact SDHB immunohistochemistry
9 Genetic Testing for Patients with PCC/PGL Pheochromocytomas/Paragangliomas represent a group of tumors with a HIGH hereditary burden (highest among hereditary benign and malignant neoplasms) Approximately 30-40% of all tumors associated with a germline mutation in a PCC/PGL predisposition gene Current literature and professional guidelines generally support the recommendation that all patients with a PCC/PGL be offered genetic testing & several specifically recommend genetic counseling to aid these patients in their decision-making NCCN, Endocrine Society America, International Symposium on PCC/PGL Consistent with ASCO recommendation (>10% rule)
10 PCC/PGL Susceptibility Genes Welander, Soederkvist, Gimm (2011) Endocr-Related Cancer ***FH is not included here; has been associated with malignant PGL
11 Genetic Testing Options & Approaches (Endo Society Practice Guidelines, JCEM. 2014)
12 PCC/PGL Predisposition Syndromes Gene (Syndrome) Inheritance (all can exhibit RP & VE**) Risk for PCC/PGL SDHA AD Not well defined; few families/mutations known; H&N? SDHAF2 (PCC/PGL-2) AD paternal transmission Up to 100% for multiple H&N PGL (based on 1 large family study) SDHB (PCC/PGL-4) AD %; ~>20% malignant; abdomen & pelvis SDHC (PCC/PGL-3) AD Solitary H&N/thoracic PGL; rare PCC & abdominal PGL SDHD (PCC/PGL-1) AD paternal transmission Up to 90%; multiple H&N PGL; some increased risk for PCC; low rate of malignancy TMEM127 AD Unknown risk; unilateral/bilateral PCC; some PGL? MAX AD paternal transmission (?) Other manifestations Biallelic mutations cause Leigh s syndrome RCC, GIST, PTC ; Carney Stratakis syndrome (CSS) RCC, GIST; CSS RCC, GIST; CSS RCC Unknown risk; mostly PCC (bilateral); initial studies up to 30% malignant **Reduced penetrance & variable expressivity
13 Hereditary Syndromes with Significant PCC Risk Syndrome (gene) von Hippel-Lindau disease (VHL) Multiple Endocrine Neoplasia type 2A & 2B (RET) Neurofibromatosis (NF1) Primary manifestations RCC, PCC, pancreatic cysts/tumors, retinal & CNS hemangioblastomas, endolymphatic sac tumors, testicular cystadenomas, broad ligament tumors Medullary thyroid cancer, PCC, primary hyperparathyroidism (MEN2A only) Café au lait spots, axillary/inguinal freckling, cutaneous & plexiform neurofibromas, PCC, Lisch nodules, optic glioma Risk for PCC/PGL 10-20% risk for PCC; PGL have been reported; ~5% risk for malignancy Can be up to and/or greater than 50%; ~4% risk for malignancy Up to 13%; ~12% risk for malignancy **All autosomal dominant syndromes with variable expressivity Adrenal characteristics Often bilateral; mean age onset 30 years; can be one of earliest manifestations; low risk with Type 1 VHL mutations Often bilateral; highest risk with 634, 883, 918 mutations; lower risk with moderate risk mutations Average age onset 42 years (similar to gen pop); typically unilateral; NF1-associated HTN could be PCC or plexiform neurofibromas
14 A closer look at H&N PGL
15 H&N PGL Characteristics Most always nonfunctional (parasympathetic) <1-3% associated with catecholamine excess Carotid body most common location (60%) 30% middle ear PGL (jugulotympanic) 10% vagal PGL Rare laryngeal, sinonasal cavity PGL?Thyroid PGL Women > men Overall low risk of malignancy Presence of metastasis only way to designate malignant tumor Bilateral/multifocal PGL in ~25% cases (hereditary) Tx can include: observation, surgery, radiation therapy Williams MD Head Neck Pathol 2017
16 H&N PGL Characteristics Smith JD et al Laryngoscope Investig Otolarngol year experience from Univ of Michigan (194 patients) Mean age of dx: 52 years (±16) 63% women 24 patients with multifocal PPGL and/or metastases (panel B) SDHD>SDHB>SDHC Single mutations in SDHA, SDHAF2, NF1 100% of SCP, multifocal or metastatic HNPGL, and bilateral CBP had germline SDHx mutation
17 Germline Testing in H&N PGL Zhu WD et al Euro J Med Genet 2015 germline testing in HNPGL patients without family history of PPGL 31% had germline mutation (8/26) SDHD>SDHB>SDHAF2 Sridhara SK et al J Neurol Surg B Skull Base 2013 Germline SDHA/AF2/B/C/D testing indicated in all cases of even apparently sporadic HNPGL 1 reported case of tympanic PGL in TMEM127 mutation carrier (Bausch B et al JAMA Oncology 2017) No known cases of HNPGL in MAX mutation carriers (Pheo predominance) Germline VHL, RET and NF1 testing highly unlikely to yield mutation in the case of apparently sporadic HNPGL
18 SDHB/C/D Penetrance Compared (Andrews KA J Med Genet 2018) SDHB = 21.8% (95% CI %) SDHC = 25% (0-57%) SDHD = 43.2% ( %) Non-probands only; lifetime
19 SDHD The p.p81l mutation (Andrews KA J Med Genet 2018)
20 Immunohistochemistry in PCC/PGL SDHB IHC can be used to screen PCC/PGL for germline SDHx mutations SDHA IHC also available SDHB IHC stains for the entire mitochondrial complex Not specific for SDHB subunit SDHA IHC is specific for the SDHA subunit Muth A et al J Internal Med 2018
21 SDH Complex in Hypoxia Nat Review Cancer 2005 Lukyanova Open Journal Endocr and Metabolic Disease 2013
22 SDH Complex Inactivation SDH complex is inactivated due to germline mutation succinate accumulates and activates HIF-α pathway Pacak et al JCO 2013
23 SDHB IHC in PCC/PGL Retained SDHB expression in sporadic PGL Williams MD Head Neck Pathol 2017 SDHB expression loss in PGL associated with germline SDHx mutation
24 SDHB IHC in PCC/PGL 1) van Nederveen FH et al Lancet Oncol 2009 SDHB IHC in 220 tumors (175 retrospective cases associated with known germline mutation; 45 prospective accompanied by germline testing) SDHB expression loss 102/102 PCC/PGL associated with germline mutation Retained expression 65/65 PCC/PGL associated with MEN2, VHL, and NF1 47/53 (89%) PCC/PGL with no germline mutation showed SDHB expression Overall: Sensitivity 100% (95% CI ) Specificity 84% (60-97)
25 SDHB IHC in PCC/PGL 2) Gill AJ et al Human Pathology 2010 SDHB IHC on 58 tumors with known germline mutation status (positive, negative, weak diffuse) 12/12 PGL associated with germline SDHx mutation showed weak diffuse or negative staining 9/10 VHL, MEN2 or NFI-associated tumors showed positive staining (1 VHL tumor = weak diffuse) 34/36 mutation negative PGL showed positive staining
26 SDHA IHC in PCC/PGL 4) Korpershoek E et al JCEM 2011 Evaluate significance of SDHA IHC in identifying patients with germline SDHA mutations SDHA IHC in 316 PCC/PGL 7 tumors showed SDHA expression loss (also showed SDHB expression loss) 4/6 patients with SDHA deficient PCC/PGL tested had germline SDHA mutation SDHB/C/D-associated tumors showed expression of SDHA Overall, suggest that the SDHB complex is degraded (?) with any SDHx mutation SDHA loss only if germline SDHA mutation
27 Case Example
28 IHC Conclusions IHC is not a replacement for germline genetic testing in any case at any time SDHB expression loss only screens for mutations in the SDHx complex, not a specific gene SDHA expression loss would highly suggest germline SDHA mutation, but still not perfect Rarity of SDHA germline mutations low yield False positives and false negatives happen, so be cautious when interpreting these results (Santi R et al Anticancer Research 2017) SDHB IHC can be useful in other tumors (RCC, GIST) SDHB/A IHC only screens for SDHx mutations, does not account for MAX, TMEM127, VHL, RET, etc. Particularly important for PCC and PGL below H&N
29 Summary All patients with PCC/PGL regardless of location, age of dx, family hx, IHC status, etc. should be referred for genetic counseling (or offered germline genetic testing) Personalized risk assessment based on location, family hx, IHC status, etc. should be conducted Unlikely to dramatically change genetic testing strategy Genetic testing critically important to inform extent of future screening/surveillance for the patient and the patient s family members
30 Samuel Hyde, MMSc, CGC Certified Genetic Counselor Clinical Cancer Genetics Questions?
A Century of observations
PARAGANGLIOMAS OF THE HEAD & NECK: AN OVERVIEW Michelle D. Williams, MD Associate Professor Dept. of Pathology Head & Neck Section UT MD Anderson Cancer Center Disclosure of Relevant Financial Relationships
More informationPhaeochromocytoma and paraganglioma: next-generation sequencing and evolving Mendelian syndromes
CME GENETICS Clinical Medicine 2014 Vol 14, No 4: 440 4 Phaeochromocytoma and paraganglioma: next-generation sequencing and evolving Mendelian syndromes Author: Eamonn R Maher A The clinical and molecular
More informationRecent Advances in the Management of
Recent Advances in the Management of Pheochromocytoma 6 : 4 Nalini S. Shah, Vijaya Sarathi, Reshma Pandit, Mumbai The 2004 WHO classification of endocrine tumors restricts the term Pheochromocytoma (PHEO)
More informationSTATE OF THE ART MANAGEMENT of PARAGANGLIOMA. IFOS, Lima, 2018
STATE OF THE ART MANAGEMENT of PARAGANGLIOMA IFOS, Lima, 2018 VINCENT C COUSINS ENT-Otoneurology Unit, The Alfred Hospital & Department of Surgery, Monash University MELBOURNE, AUSTRALIA PARAGANGLIOMAS
More informationDisclosures 3/27/2017. Case 5. Clinical History. Disclosure of Relevant Financial Relationships
Hereditary Cancer Predisposition in Children Case 5 Cristina R. Antonescu, MD Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence
More informationSystemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.
Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works. Arturo Loaiza-Bonilla, MD, FACP Assistant Professor of Clinical Medicine
More informationPheochromocytoma and Paraganglioma in Neurofibromatosis type 1: frequent surgeries and cardiovascular crises indicate the need for screening
Petr and Else Clinical Diabetes and Endocrinology (2018) 4:15 https://doi.org/10.1186/s40842-018-0065-4 RESEARCH ARTICLE Open Access Pheochromocytoma and Paraganglioma in Neurofibromatosis type 1: frequent
More informationGenetics of Paragangliomas and Pheochromocytomas
Genetics of Paragangliomas and Pheochromocytomas Alexandre Persu, M.D.-Ph.D. Cardiology Department Cliniques Universitaires Saint-Luc Université Catholique de Louvain Pheochromocytoma and paraganglioma
More information5/1/2010. Genetic testing in patients with endocrine tumors. Genetic testing in Patients with Endocrine Tumors
Genetic testing in patients with endocrine tumors Why? Jessica E. Gosnell MD Assistant Prof of Surgery April 30, 2010 Genetic testing in Patients with Tumors Indications & Interpretation Germline mutations
More informationUpdate in Pheochromocytoma/Paraganglioma: Focus on Diagnosis and Management
Update in Pheochromocytoma/Paraganglioma: Focus on Diagnosis and Management Ohk-Hyun Ryu, MD. Associate Professor, Department of Internal Medicine Division of Endocrinology and Metabolism College of Medicine,
More informationOverview of the immunohistochemical and sequencing results from 35 non-paraganglionic tumors
Supplemental Figure 1. Overview of the immunohistochemical and sequencing results from 35 non-paraganglionic tumors arising in 26 SDH mutation carriers. Abbreviations Supplemental Figure 1: SDH: succinate
More informationBilateral adrenal pheochromocytoma with a germline L790F mutation in the RET oncogene
J Korean Surg Soc 2012;82:185-189 http://dx.doi.org/10.4174/jkss.2012.82.3.185 CASE REPORT JKSS Journal of the Korean Surgical Society pissn 2233-7903 ㆍ eissn 2093-0488 Bilateral adrenal pheochromocytoma
More informationDiagnostic et prise en charge des phéochromocytomes (PH) et paragangliomes (PG)
Diagnostic et prise en charge des phéochromocytomes (PH) et paragangliomes (PG) PF Plouin, L Amar et AP Gimenez-Roqueplo COMETE, ENS@T et HEGP/Université Paris-Descartes Chromaffin tumors: PH and PG PH
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationGenética del Feocromocitoma/Paraganglioma.
Genética del Feocromocitoma/Paraganglioma. Mercedes Robledo, PhD Head of the Hereditary Endocrine Cancer Group Human Cancer Genetics Programme CNIO, Madrid, Spain. mrobledo@cnio.es High susceptibility
More informationPheochromocytoma and paraganglioma syndromes: genetics and management update
Curr Oncol, Vol. 21, pp. e8-17; doi: http://dx.doi.org/10.3747/co.21.1579 GENETICS AND MANAGEMENT OF PHEO AND PGL SYNDROMES ORIGINAL ARTICLE Pheochromocytoma and paraganglioma syndromes: genetics and management
More informationFamilial paraganglioma: A novel presentation of a case and response to therapy with radiolabelled MIBG
HORMONES 2004, 3(2):127- Case report Familial paraganglioma: A novel presentation of a case and response to therapy with radiolabelled MIBG Justin K. Lawrence 1, Eamonn R. Maher 2, Richard Sheaves 3, Ashley
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient
More informationWhat a patient should know about paraganglioma (PGL): For our children, for our future. Karel Pacak Ph:
What a patient should know about paraganglioma (PGL): For our children, for our future Karel Pacak Ph: 301-402-4594 karel@mail.nih.gov PHEO/PGL: definition/location PHEOs/PGLs are neuroendocrine tumors
More informationAccepted 5 June 2008 Published online 15 December 2008 in Wiley InterScience ( DOI: /hed.20930
CASE REPORT Russell B. Smith, MD, Section Editor DIAGNOSIS AND MANAGEMENT OF HEREDITARY PARAGANGLIOMA SYNDROME DUE TO THE F933>X67 SDHD MUTATION Monica L. Marvin, MS, 1 Carol R. Bradford, MD, 2 James C.
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role
More informationDiagnostic Paediatric Pathology
Annals of Diagnostic Paediatric Pathology 2007, 11(1 2):15 19 Copyright by Polish Paediatric Pathology Society Annals of Pheochromocytoma in children and adolescents based on Polish Pheochromocytoma Registry
More informationGenetics and Genomics in Endocrinology
Genetics and Genomics in Endocrinology Dr. Peter Igaz MD MSc PhD 2 nd Department of Medicine Faculty of Medicine Semmelweis University Genetics-based endocrine diseases I. Monogenic diseases: Multiple
More informationGENETICS IN ENDOCRINE ONCOLOGY A PRACTICAL APPROACH
GENETICS IN ENDOCRINE ONCOLOGY A PRACTICAL APPROACH From Classical Syndromes to New Associations. Tobias Else, MD, Assistant Professor Endocrine Oncology & Cancer Genetics Clinic Comprehensive Clinical
More informationSDHC MUTATIONS ARE ASSOCIATED WITH CARDIAC PARAGANGLIOMAS: A CASE REPORT OF A PATIENT WITH A DOPAMINE-SECRETING TUMOR AND REVIEW OF THE LITERATURE
Case Report SDHC MUTATIONS ARE ASSOCIATED WITH CARDIAC PARAGANGLIOMAS: A CASE REPORT OF A PATIENT WITH A DOPAMINE-SECRETING TUMOR AND REVIEW OF THE LITERATURE Daniela Guelho, MD 1 ; Daniela Stefania Trifu,
More informationGenetic Testing for Hereditary Cancer Susceptibility Syndromes
Medical Coverage Policy Genetic Testing for Hereditary Cancer Susceptibility Syndromes Table of Contents Effective Date... 1/15/2018 Next Review Date... 7/15/2018 Coverage Policy Number... 0518 Related
More informationReview Article Paragangliomas/Pheochromocytomas: Clinically Oriented Genetic Testing
International Journal of Endocrinology, Article ID 794187, 14 pages http://dx.doi.org/10.1155/2014/794187 Review Article Paragangliomas/Pheochromocytomas: Clinically Oriented Genetic Testing Rute Martins
More informationGastrointestinal Stromal Tumor Causes, Risk Factors, and Prevention
Gastrointestinal Stromal Tumor Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors
More informationSynchronous bilateral pheochromocytomas and paraganglioma with novel germline mutation in MAX: a case report
Shibata et al. Surgical Case Reports (2017) 3:131 DOI 10.1186/s40792-017-0408-x CASE REPORT Synchronous bilateral pheochromocytomas and paraganglioma with novel germline mutation in MAX: a case report
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationPheochromocytoma: updates on management strategies
Pheochromocytoma: updates on management strategies Hanaa Tarek El-Zawawy Lecturer of Internal Medicine and Endocrinology Alexandria University Contents: Introduction Clinical presentation Investigations
More informationPituitary, Parathyroid Pheochromocytomas & Paragangliomas: The 4 Ps of NETs
Pituitary, Parathyroid Pheochromocytomas & Paragangliomas: The 4 Ps of NETs Shereen Ezzat, MD, FRCP(C), FACP Professor Of Medicine & Oncology Head, Endocrine Oncology Princess Margaret Hospital/University
More informationRole of succinate dehydrogenase in pheochromocytomas and paragangliomas
Role of succinate dehydrogenase in pheochromocytomas and paragangliomas PhD thesis Nikoletta Katalin Lendvai Doctoral School of Clinical Medicine Semmelweis University Supervisor: Attila Patócs MD, Ph.D,
More informationRenal tumours: use of immunohistochemistry & molecular pathology. Dr Lisa Browning John Radcliffe Hospital Oxford
Renal tumours: use of immunohistochemistry & molecular pathology Dr Lisa Browning John Radcliffe Hospital Oxford Renal tumours: the use of immunohistochemistry & molecular pathology Classification of RCC
More informationNeurocutaneous Syndromes. Phakomatoses
Neurocutaneous Syndromes Phakomatoses Financial Disclosures I have NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT Neurocutaneous Syndomes Definition Entities Diagnosis/ Presentation
More informationSDHD GENE MUTATIONS: LOOKING BEYOND HEAD AND NECK TUMORS
Case Report SDHD GENE MUTTIONS: LOOKING EYOND HED ND NECK TUMORS Sushma Kadiyala, MD 1,2* ; Yasmin Khan, MD 1,2* ; Valeria de Miguel, MD 3* ; Megan N. Frone, MS, CGC 4 ; Fiemu Nwariaku, MD 5 ; Jennifer
More informationCalculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers
Familial Cancer (2017) 16: 130 DOI 10.1007/s10689-016-9923-3 ORIGINAL ARTICLE Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers Karin Eijkelenkamp 1 Thamara
More informationA KINDRED WITH a RET CODON Y791F MUTATION PRESENTING WITH HIRSCHSPRUNG S S DISEASE.
A KINDRED WITH a RET CODON Y791F MUTATION PRESENTING WITH HIRSCHSPRUNG S S DISEASE. ד"ר מרב פרנ קל ד גנית ברק גרוס דיויד פרופסור השרות לאנדוקרינ ולוגיה ומטבוליזם ירושלים ה דסה עין כר םם, Case Report 36
More informationSummary. (Received 20 August 2012; returned for revision 6 September 2012; finally revised 10 October 2012; accepted 10 October 2012)
Clinical Endocrinology (2013) 78, 898 906 doi: 10.1111/cen.12074 ORIGINAL ARTICLE Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma,
More informationDisclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1
Disclosure Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-1 Case Presentation A 43 year old male, with partial nephrectomy for a right kidney mass 2013 MFMER slide-2 2013
More informationConferencia III: Dilemas en el tratamiento de Feocromocitomas y Paragangliomas. Dilemmas in Management of Pheochromocytoma and Paraganglioma
Conferencia III: Dilemas en el tratamiento de Feocromocitomas y Paragangliomas Dilemmas in Management of Pheochromocytoma and Paraganglioma William F. Young, Jr., MD, MSc Mayo Clinic Rochester, MN, USA
More informationWhat is the primary location of mitochondrial respiratory complexes? These complexes are embedded in the inner mitochondrial membrane.
Interactive Questions Question 1: What is the primary location of mitochondrial respiratory complexes? Outer mitochondrial membrane Mitochondrial inter-membrane space Inner mitochondrial membrane These
More informationGermline Multigene Panel Testing in Oncology: Genetic Counseling Perspective
Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families
More informationPheochromocytomas (PHEOs) are rare catecholamineproducing
Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6- F-Fluorodopamine PET Henri J.L.M. Timmers 1,2, Jorge A. Carrasquillo
More informationADRENAL MEDULLARY DISORDERS: PHAEOCHROMOCYTOMAS AND MORE
ADRENAL MEDULLARY DISORDERS: PHAEOCHROMOCYTOMAS AND MORE DR ANJU SAHDEV READER AND CONSULTANT RADIOLOGIST QUEEN MARY UNIVERSITY AND ST BARTHOLOMEW S HOSPITAL BARTS HEALTH, LONDON, UK DISCLOSURE OF CONFLICT
More informationpatient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention
patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime
More informationTHE FACTS YOU NEED TO KNOW
PHEOCHROMOCYTOMA THE FACTS YOU NEED TO KNOW Pheochromocytoma is a part of the pheochromocytoma and paraganglioma group of syndromes. A pheochromocytoma is a tumor arising in the adrenal gland medulla.
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/887/2538 holds various files of this Leiden University dissertation. Author: Boetzelaer-van Hulsteijn, Leonie Theresia van Title: Paragangliomas Pictured Issue
More informationThe Genetics of VHL. Proper tissue growth - controlled traffic. How human cells and tissue grow and die?
How human cells and tissue grow and die? The Genetics of VHL Xia Wang MD PhD Oct, 2017 Proper tissue growth - controlled traffic Normal tissue growth is regulated by many genetic factors Safe traffic is
More informationGenetic Testing of Inherited Cancer Predisposition Genetic Testing - Oncology
Genetic Testing of Inherited Cancer Predisposition Genetic Testing - Oncology Policy Number: Original Effective Date: MM.02.010 05/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationInformation for You and Your Family
Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the
More informationAdrenal masses in infancy and childhood: A clinical and radiological overview M. Mearadji
Adrenal masses in infancy and childhood: A clinical and radiological overview M. Mearadji International Foundation for Pediatric Imaging Aid Introduction Neoplastic adrenal masses usually originate from
More informationResult Navigator. Positive Test Result: RET. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: RET Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationThe Clinical Approach to Wild Type GIST. Margaret von Mehren, MD Professor and Director of Sarcoma Oncology Fox Chase Cancer Center
The Clinical Approach to Wild Type GIST Margaret von Mehren, MD Professor and Director of Sarcoma Oncology Fox Chase Cancer Center Disclosure slide Scientific Advisor to Novartis, Pfizer, Merck Research
More informationCurrent Approach to Pheochromocytoma
October 01, 2006 By Cord Sturgeon, MD [1] and Peter Angelos, MD, PhD [2] Pheochromocytomas are tumors of the neural crest-derived chromaffin cells. The hallmark of this rare and fascinating neoplasm is
More informationManagement of pediatric pheochromocytoma
Jemis, 4 (1) 2016 Management of pediatric pheochromocytoma A review of the literature C. Muriello C. Gambardella G. Siciliano G. Izzo E. Tartaglia D. Esposito S. Reina R. Patrone L. Santini G. Conzo Table
More informationParagangliomas and paraganglioma syndromes
OPEN ACCESS Review Article Paragangliomas and paraganglioma syndromes Abstract Paragangliomas are rare tumors of neural crest origin. They are benign in the majority of cases and are characterized by a
More informationPheochromocytoma AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY ILLINOIS CHAPTER OCTOBER 13, 2018
Pheochromocytoma AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY ILLINOIS CHAPTER OCTOBER 13, 2018 Steven A. De Jong, M.D., FACS, FACE Professor and Vice Chair of Surgery Chief, Division of General Surgery
More informationCardiology Department, Sf. Spiridon Clinical Emergency Hospital, Iasi, Romania, 2 Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania
Cardiovascular complications induced by pheochromocytoma associated with neurofibromatosis type 1 (von Recklinghausen s disease) case report and review of literature Ovidiu Mitu 1,*, Dan Tesloianu 1, Ionut
More informationREVIEW. Pheochromocytoma: The Expanding Genetic Differential Diagnosis
REVIEW Pheochromocytoma: The Expanding Genetic Differential Diagnosis Jennifer Bryant, Jennifer Farmer, Lisa J. Kessler, Raymond R. Townsend, Katherine L. Nathanson Pheochromocytomas and paragangliomas
More informationTHE HIGHS AND LOWS OF ADRENAL GLAND PATHOLOGY
THE HIGHS AND LOWS OF ADRENAL GLAND PATHOLOGY Symptoms of Adrenal Gland Disorders 2 Depends on whether it is making too much or too little hormone And on what you Google! Symptoms include obesity, skin
More informationAre you at risk of Hereditary Cancer? Your Guide to the Answers
Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,
More informationADRENALECTOMY IN THE ELDERLY: EMPHASIS ON PHEOCHROMOCYTOMA
ADRENALECTOMY IN THE ELDERLY: EMPHASIS ON PHEOCHROMOCYTOMA David S. Pertsemlidis, Assistant Clinical Professor and Demetrius Pertsemlidis, Clinical Professor Department of Surgery, Mount Sinai School of
More informationExpert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian
Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian ANNOUNCER OPEN: Welcome to CME on ReachMD. This segment, entitled Inherited Susceptibility to Cancer: What Do Primary Care Providers
More informationClinical Cancer Genetics
Clinical Cancer Genetics Lisen Axell, MS, CGC University of Colorado Cancer Center Individuals with cancer Making surgical decisions (lump vs. mast) Making treatment decisions (XRT) Concerns for additional
More informationSuperior mediastinal paraganglioma associated with von Hippel-Lindau syndrome: report of a case
Takahashi et al. World Journal of Surgical Oncology 2014, 12:74 WORLD JOURNAL OF SURGICAL ONCOLOGY CASE REPORT Open Access Superior mediastinal paraganglioma associated with von Hippel-Lindau syndrome:
More informationPheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline
SPECIAL FEATURE Clinical Practice Guideline Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline Jacques W. M. Lenders, Quan-Yang Duh, Graeme Eisenhofer, Anne-Paule Gimenez-Roqueplo,
More informationRECURRENT ADRENAL DISEASE. Megan Applewhite Endorama 2/19/2015 SR , SC
RECURRENT ADRENAL DISEASE Megan Applewhite Endorama 2/19/2015 SR 2412318, SC 3421561 Category: Adrenal Attendings: Angelos & Grogan PATIENT #1 36yo woman with a hx of Cushing s Syndrome and right adrenalectomy
More informationpatient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention
patient guide RenalNext genetic testing for hereditary kidney cancer Because knowing your risk can mean early detection and prevention Know the Basics Risk factors for developing kidney cancer include
More informationDiagnosis of pheochromocytoma with special emphasis on MEN2 syndrome
HORMONES 2009, 8(2):111-116 Review Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome Karel Pacak 1, Graeme Eisenhofer 2, Ioannis Ilias 3 1 Reproductive and Adult Endocrinology Program,
More informationGenetic Testing for Heredity Cancer Susceptibility
Clinical Appropriateness Guidelines Genetic Testing for Heredity Cancer Susceptibility EFFECTIVE OCTOBER 14, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2064-1017 Table of Contents Scope...
More informationNeuroendocrine Carcinoma. Lebanon Neuroendocrine Neoplasms of H&N Nov /7/2011. Broad Classification:
H&N Neuroendocrine Neoplasms: Classification and Diagnostic Considerations Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Broad Classification: A. Epithelial:
More informationDoes Cancer Run in Your Family?
Does Cancer Run in Your Family? Nancie Petrucelli, MS, CGC Clinical Assistant Professor Certified Genetic Counselor/Coordinator Cancer Genetic Counseling Service Karmanos Cancer Institute Wayne State University
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationParagangliomas (PGLs) and pheochromocytomas
ORIGINAL ARTICLE A SDHC Founder Mutation Causes Paragangliomas (PGLs) in the French Canadians: New Insights on the SDHC-Related PGL Isabelle Bourdeau, Solange Grunenwald, Nelly Burnichon, Emmanuel Khalifa,
More informationONCOGENETIC TESTING FOR PERSONS WITH HEREDITARY ENDOCRINE CANCER SYNDROMES
KCE REPORT 242Cs ABSTRACT ONCOGENETIC TESTING FOR PERSONS WITH HEREDITARY ENDOCRINE CANCER SYNDROMES 2015 www.kce.fgov.be KCE REPORT 242Cs GOOD CLINICAL PRACTICE ABSTRACT ONCOGENETIC TESTING FOR PERSONS
More informationSUCCINATE DEHYDROGENASE SUBUNIT B MUTATION PRESENTING WITH SPERMATIC CORD AND NECK PARAGANGLIOMA
Case Report SUCCINATE DEHYDROGENASE SUBUNIT B MUTATION PRESENTING WITH SPERMATIC CORD AND NECK PARAGANGLIOMA Caroline Bachmeier, MD 1 ; Leslie Kuma, MBBS, FRCPA 2 ; Michael Collins, MBBS, FRANZCR 3 ; Kunwarjit
More informationKidney Cancer Causes, Risk Factors, and Prevention
Kidney Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for kidney cancer.
More informationTHYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine
THYROID CANCER IN CHILDREN Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine Thyroid nodules Rare Female predominance 4-fold as likely to be malignant Hx Radiation exposure?
More informationInnovativeHealth SINAS DRAMIS LAW FIRM. Michigan SUMMER 2017 AUTO NO-FAULT SPECIAL ISSUE CATHOLIC CHARITIES. NeuroTrauma Association THE LEGACY OF THE
Can be accessed online at: http://www.emagcloud.com/innovativehealthmagazine/ihm422017online4/#/100/ InnovativeHealth Michigan SUMMER 2017 W E L L N E S S A N D H E A L T H C A R E M A G A Z I N E ONE
More informationIntroduction. Methods and materials. 68 Ga-DOTATATE PET CT imaging in carotid body paragangliomas. Patients
https://doi.org/10.1007/s12149-018-1242-3 SHORT COMMUNICATION 68 Ga-DOTATATE PET CT imaging in carotid body paragangliomas Duygu Has Şimşek 1 Yasemin Şanlı 2 Serkan Kuyumcu 2 Bora Başaran 3 Ayşe Mudun
More informationSo how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent.
Welcome. My name is Amanda Brandt. I am one of the Cancer Genetic Counselors at the University of Texas MD Anderson Cancer Center. Today, we are going to be discussing how to identify patients at high
More informationUniversitätsklinikum Carl Gustav Carus. Graeme Eisenhofer
Universitätsklinikum Carl Gustav Carus DIE DRESDNER. Biochemistry of Phaeochromocytoma Graeme Eisenhofer Institut für Klinische Chemie und Laboratoriumsmedizin and Medizinische Klinik III, Universitätsklinikum
More informationPHEOCHROMOCYTOMAS AND PARAGANGLIOMAS
PHEOCHROMOCYTOMAS AND PARAGANGLIOMAS FROM DNA TO THE DAILY CLINICAL PRACTICE BART-JEROEN PETRI The printing of this thesis was financially supported by: Ipsen Novartis KCI Pfizer GSK Jurriaanse Stichting
More informationA Case of Pancreatic Neuroendocrine Tumor presenting Iron Deficiency Anemia in a Patient with Neurofibromatosis Type 1
A Case of Pancreatic Neuroendocrine Tumor presenting Iron Deficiency Anemia in a Patient with Neurofibromatosis Xueyu Sun 1, Yanan Yu 1, Yueping Jiang 1, Deming Li 1 1 Department of Gastroenterology, The
More informationCancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor
Cancer Survivorship Symposium Cancer and Heredity January 16, 2017 Jeanne P. Homer, MS Licensed Certified Genetic Counselor Outline Cancer and Heredity Hereditary Cancer Risk Assessment & Genetic testing
More informationAbstract. Samuel Hahn, M.D. 1 James N. Palmer, M.D. 1 Nithin D. Adappa, M.D. 1
19 A Catecholamine-Secreting Skull Base Sinonasal Paraganglioma Presenting with Labile Hypertension in a Patient with Previously Undiagnosed Genetic Mutation Samuel Hahn, M.D. 1 James N. Palmer, M.D. 1
More informationPHEOCHROMOCYTOMA. A Atrash. Moderator: K Govender. 2 October 2015 No: 30. School of Clinical Medicine. Discipline of Anaesthesiology and Critical Care
2 October 2015 No: 30 PHEOCHROMOCYTOMA A Atrash Moderator: K Govender School of Clinical Medicine Discipline of Anaesthesiology and Critical Care Page 1 of 22 CONTENTS Introduction.....3 Incidence......3
More informationNEOPLASMS OF THE THYROID PATHOLOGY OF PARATHYROID GLANDS. BY: Shifaa Qa qa
NEOPLASMS OF THE THYROID PATHOLOGY OF PARATHYROID GLANDS BY: Shifaa Qa qa Neoplasmas of the thyroid thyroid nodules Neoplastic ---- benign, malignant Non neoplastic Solitary nodules ----- neoplastic Nodules
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationWELCOME. Taking Care of Your Health. April 30, 8 am to noon
WELCOME Taking Care of Your Health April 30, 8 am to noon Cancer: Know Your Risk Emily Kuchinsky, MS, CGC, Certified Genetic Counselor Sporadic Cancer Lifetime Probability- Women Family Cluster Risk factors
More informationLecture outline. Disclosure. Nothing to disclose. Basic and clinical research in pheochromocytoma (PHEO): a winning combination
Basic and clinical research in pheochromocytoma (PHEO): a winning combination Karel Pacak karel@mail.nih.gov Disclosure Nothing to disclose National Institutes of Health Lecture outline The lecture will
More informationCase 1 PLEASE TURN OFF YOUR CELL PHONES 3/28/2017. Disclosure of Relevant Financial Relationships. Disclosure of Relevant Financial Relationships
PLEASE TURN OFF YOUR CELL PHONES Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME disclose
More informationWhat s New in Pathology of Genitourinary Tumors. Jiaoti Huang, MD, PhD Department of Pathology Duke University School of Medicine
What s New in Pathology of Genitourinary Tumors Jiaoti Huang, MD, PhD Department of Pathology Duke University School of Medicine Kidney Tumors Multilocular cystic renal neoplasm of low malignant potential
More informationYear 2003 Paper two: Questions supplied by Tricia
question 43 A 42-year-old man presents with a two-year history of increasing right facial numbness. He has a history of intermittent unsteadiness, mild hearing loss and vertigo but has otherwise been well.
More informationPHEOCHROMOCYTOMA. Anita Chiu, MD Kings County Hospital Center January 13, 2011
PHEOCHROMOCYTOMA Anita Chiu, MD Kings County Hospital Center January 13, 2011 Case Presentation 62 year old female from Grenada with longstanding HTN, DM, CRI Complaints of palpitations for years Abdominal
More informationMultidisciplinary management of retroperitoneal sarcomas
Multidisciplinary management of retroperitoneal sarcomas Eric K. Nakakura, MD UCSF Department of Surgery UCSF Comprehensive Cancer Center San Francisco, CA 7 th Annual Clinical Cancer Update North Lake
More informationDiagnosis of silent pheochromocytoma and paraganglioma
Expert of Endocrinology & Metabolism ISSN: 1744-6651 (Print) 1744-8417 (Online) Journal homepage: http://www.tandfonline.com/loi/iere20 Diagnosis of silent pheochromocytoma and paraganglioma Roderick Clifton-Bligh
More informationAdrenal Disorders. Disclosure: I do not have any conflicts of interest
Adrenal Disorders Robert G. Dluhy, M.D. Disclosure: I do not have any conflicts of interest Robert G. Dluhy, MD Case 1 28 y.o. male with no significant past medical history presents with 6-8 months of
More information